Bone disease in renal transplant recipients

Sm, Sprague; Ølgaard, Klaus; Salusky, I. B.; Silver, J R

doi:10.1093/med/9780199559176.003.029

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone mineral loss in RTx patients can be well explained by the combinations of the persistence of pre‐RTx bone disease at post‐RTx period, negative effects of immunosuppressive treatments (especially CS), AR attacks, and allograft dysfunction . The metabolic changes in the post‐RTx period and the steroid‐based treatment regimens can cause bone quality abnormalities in RTR.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The evaluation of bone metabolism in children with renal transplantation

Büyükkaragöz

Bakkaloğlu

Kandur

et al. 2015

Pediatric Transplantation

View full text Add to dashboard Cite

This study aims to evaluate BMD and bone biomarkers and to investigate the effects of immunosuppressives on bone disease after RTx. Thirty-three RTR aged 16.7 ± 3.7 yr and healthy controls (n = 32) were enrolled. There was no difference between pre-RTx BMD and BMD at the time of study (45.9 ± 30.9 months after RTx), while both values were lower than controls (p < 0.01 and p < 0.05, respectively). Worst BMD scores were obtained at sixth month after RTx (-0.2 ± 0.9) and best at fourth year (1.4 ± 1.3). 25-hydroxy-(OH) vitamin D and OPG were higher in RTR (p < 0.001). BMD z scores negatively correlated with OPG and cumulative CS doses at the time of study (r = -0.344, p < 0.05 and r = -0.371, p < 0.05, respectively). Regression analysis revealed OPG as the only predictor of BMD (β -0.78, 95% CI -0.004 to -0.013, p < 0.001). The increase in OPG, a significant predictor of BMD, could either be secondary to graft dysfunction or for protection against bone loss. CS doses should be minimized to avoid their untoward effects on bone metabolism.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The metabolic changes in the post‐RTx period and the steroid‐based treatment regimens can cause bone quality abnormalities in RTR. CS treatment causes a decrease in trabecular BMD and an increase in cortical BMD , and it diminishes bone formation especially in the early post‐RTx period .…”

Section: Discussionmentioning

confidence: 99%